OTEZLA

Peak

apremilast

NDAORALTABLET
Approved
Sep 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20

Clinical Trials (5)

NCT06863493Phase 2/3Not Yet Recruiting

Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis Patients

Started Jun 2025
NCT05601492Phase 1Withdrawn

Adherence to Otezla

Started Jun 2025
0
Psoriasis
NCT06122649Phase 3Completed

A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)

Started Nov 2023
203 enrolled
Plaque Psoriasis
NCT06088199Phase 3Active Not Recruiting

A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis

Started Oct 2023
51 enrolled
Plaque Psoriasis
NCT05767047Phase 3Recruiting

A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis

Started Mar 2023
48 enrolled
Behçet's DiseaseJuvenile Psoriatic Arthritis